Cu64/67 is owned by Clarity (NSW based). SAR-bisPSMA - Next-Generation, Highly Targeted Prostate Cancer Theranostic - Clarity (claritypharmaceuticals.com)
They are not listed, hadn't heard they were planning for ASX listing.
Cu64 has theoretical advantages. With a 12h half life, you can do serial imaging - you get an idea of disease sites the injection gets to after a few hours, then a day later you can see if those sites retained the tracer and potentially even stretch it out to 2 days.
This is useful for estimating dosimetry and the actual radiation dose delivered to sites of disease.
With Ga68 (~1h half life), you cannot assess for retention beyond 3-4h, so even if a disease site takes up the tracer very strongly, it might dissociate after 8 hours and you'd never know. So if you were to administer Lu-177 bound to the ligand, there would only be treatment at the disease site for a short while (ie. may not work).
Same with Zr89 btw (TLX using this for TLX250 cdx, even longer half life at 78h.)
hope that makes senes
- Forums
- ASX - By Stock
- Competition
Cu64/67 is owned by Clarity (NSW based). SAR-bisPSMA -...
-
- There are more pages in this discussion • 230 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.19 |
Change
0.000(0.00%) |
Mkt cap ! $6.421B |
Open | High | Low | Value | Volume |
0.0¢ | $19.19 | $18.78 | $472.4K | 24.61K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1568 | $20.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.24 | 1629 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1568 | 20.740 |
17 | 7136 | 20.140 |
1 | 239 | 20.110 |
2 | 521 | 20.000 |
1 | 2 | 19.730 |
Price($) | Vol. | No. |
---|---|---|
18.240 | 3772 | 7 |
18.290 | 1953 | 1 |
18.580 | 1481 | 8 |
18.590 | 158 | 2 |
18.610 | 775 | 4 |
Last trade - 09.56am 19/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
Day chart unavailable